SAN DIEGO / Apr 05, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which provides updates on key environmental, social, and governance (ESG) initiatives that are aligned with Dexcom’s core values and business strategy.
“At Dexcom, we recognize and value the significant trust placed in our company not only by our global customer base, but also our employees and their families, our communities and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We believe that by advancing the interests of our key stakeholders, we can both support the success of our business and drive greater health and economic benefits for our users and global health systems.”
Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The annual report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.
Highlights from this year’s report include:
Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at the following link: Dexcom Sustainability Report. All data in the report reflects fiscal year 2022, unless noted otherwise.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Last Trade: | US$75.26 |
Daily Change: | -2.54 -3.26 |
Daily Volume: | 2,568,221 |
Market Cap: | US$29.400B |
December 17, 2024 November 19, 2024 October 24, 2024 September 04, 2024 August 28, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB